MISSED OUT ON THE LATEST CLINICAL GUIDELINE ANNOUNCEMENTS?
No problem, we’ve got you covered! Here’s a list to all guidelines and FDA approvals that were published last month.
- Role of Nonstatin Therapies for LDL-Cholesterol Lowering in the Management of Atherosclerotic Cardiovascular Disease Risk
- TPMT and NUDT15 Genotyping Recommendations
- Mismatch Repair and Microsatellite Instability Testing for Immune Checkpoint Inhibitor Therapy
- Chemotherapy and Targeted Therapy for Human Epidermal Growth Factor Receptor 2–Negative Metastatic Breast Cancer That Is Either Endocrine-Pretreated or Hormone Receptor–Negative
EXCLUSIVE SOCIETY GUIDELINES AND MANY MORE!
Search, bookmark, add notes and create your personal clinical guideline library with your digital copy or one of our society and specialty subscription bundles.
August 1, 2022 Stelara
Treatment of pediatric patients six years of age and older with active psoriatic arthritis (PsA).
August 2, 2022 Kyzatrex
Oral testosterone replacement therapy indicated in adult males for conditions associated with a deficiency or absence of endogenous testosterone, also known as hypogonadism.
August 2, 2022 Cimerli
Multiple indications as biosimilar to Lucentis.
August 3, 2022 Juvéderm Volux XC
For the improvement of jawline definition in adults over the age of 21 with moderate to severe loss of jawline definition.
August 5, 2022 Enhertu
Treatment of patients with unresectable or metastatic HER2-low breast cancer.
August 5, 2022 Calquence
Multiple indications as new tablet formulation.
August 5, 2022 Myfembree
Management of moderate to severe pain associated with endometriosis in pre-menopausal women, with a treatment duration of up to 24 months.
August 11, 2022 Xofluza
For the treatment of acute uncomplicated influenza in otherwise healthy children aged five to less than 12 years of age who have been symptomatic for no more than 48 hours.
August 11, 2022 Enhertu
Treatment of adult patients with unresectable or metastatic non-small cell lung cancer (NSCLC) whose tumors have activating HER2 (ERBB2) mutations, as detected by a Food and Drug Administration (FDA)-approved test, and who have received a prior systemic therapy.
August 17, 2022 Zynteglo
For adult and pediatric patients with beta-thalassemia who require regular red blood cell transfusions.
August 18, 2022 Mirena
Extending the duration of use for up to 8 years of pregnancy prevention. Previously, the intrauterine device was indicated for contraception for up to 7 years.
August 19, 2022 Auvelity
For the treatment of major depressive disorder (MDD) in adults.
August 23, 2022 Proclaim™ Plus
Management of chronic pain.
August 24, 2022 Imbruvica
Treatment of pediatric patients one year and older with chronic graft-versus-host disease (cGVHD) after failure of one or more lines of systemic therapy.
August 26, 2022 Pemazyre
For adults with relapsed or refractory myeloid/lymphoid neoplasms with FGFR1 rearrangement.
August 31, 2022 Xenpozyme
For the treatment of non-central nervous system (non-CNS) manifestations of acid sphingomyelinase deficiency (ASMD) in adult and pediatric patient.
Copyright © 2022 Guideline Central, All rights reserved.